Core Viewpoint - Celularity Inc. has resolved its compliance issues with Nasdaq, allowing its stock to continue trading on the Nasdaq Stock Market after curing its filing delinquency [1][2][3] Group 1: Compliance Resolution - The Nasdaq Listing Qualifications Hearings Panel cancelled the scheduled hearing regarding Celularity's non-compliance with Nasdaq Listing Rule 5250(c)(1) after the company filed its overdue quarterly reports [1][2] - Celularity filed its Form 10-Q for the period ended March 31, 2024, on October 16, 2024, and its Form 10-Q for the period ended June 30, 2024, on November 7, 2024, achieving compliance with Nasdaq requirements [2] Group 2: Company Statements and Challenges - Robert J. Hariri, CEO of Celularity, expressed satisfaction in meeting Nasdaq's requirements and emphasized the company's commitment to transparency and regulatory compliance [3] - The delays in filing were attributed to significant financial challenges in the biotechnology sector, which limited access to capital and affected the company's ability to secure essential audit and financial advisory services [3] Group 3: Company Overview - Celularity Inc. is focused on developing and commercializing advanced biomaterial products and placental-derived cell therapies targeting aging-related diseases, cancer, and immune disorders [4] - The company aims to leverage the unique biology of the placenta to create effective, accessible, and affordable therapeutic solutions for significant unmet global needs [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, $0.0001 par value per share CELU The Nasdaq Stock Market LLC Warrants, each exercisable for one-tenth of one share of Class A Common Stock at an exercise price of $11.50 per one-tenth of one share CELUW The Nasdaq Stock Market LLC FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38914 Celularity Inc. (Exact name of registrant as specified in its charter) Delaware 83-1702591 (State or other jurisdiction of ...

Core Viewpoint - Celularity Inc. is seeking a hearing before the Nasdaq Hearings Panel to address its non-compliance with Nasdaq Listing Rule 5250(c)(1) and to request an extension for regaining compliance [1][2][3] Compliance Issues - Celularity received a formal notice from Nasdaq on August 22, 2024, regarding non-compliance due to delayed filings of its quarterly reports on Forms 10-Q for the periods ended March 31, 2024, and June 30, 2024 [2] - An extension was granted until October 14, 2024, but Nasdaq notified Celularity on October 16, 2024, that it would be suspended from trading on October 25, 2024, unless an appeal was filed by October 23, 2024 [2] Appeal and Compliance Plan - On October 23, 2024, Celularity filed an appeal and an amended compliance plan, which temporarily stays the suspension or delisting action [3] - The company has filed its Form 10-Q for the period ended March 31, 2024, and is preparing the Form 10-Q for the period ended June 30, 2024 [3] - The Hearings Panel may grant Celularity up to an additional 180 days to regain compliance, but there is no assurance of a successful appeal or compliance [3] Company Overview - Celularity Inc. is a regenerative medicine company focused on developing and commercializing advanced biomaterial products and placental-derived cell therapies [4] - The company's therapeutic programs target aging-related diseases, cancer, and immune disorders using various cell types derived from the postpartum placenta [4] - Celularity aims to address significant unmet global needs for effective and affordable therapies by leveraging the unique biology of the placenta [4]

FLORHAM PARK, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the "Company"), a regenerative medicine company developing and commercializing placental-derived technologies, today announced that it has received a formal notice from the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") on October 16, 2024, indicating that the Company is subject to delisting due to its inability to timely file its Forms 10-Q for the the periods ended March 31, 2024, and June 30 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38914 Celularity Inc. (Exact name of registrant as specified in its charter) Delaware 83-1702591 (State or other jurisdiction o ...

FLORHAM PARK, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a regenerative and cellular medicine company, today announced that it had added to its commercial portfolio of placental-derived advanced biomaterial products with the acquisition of Rebound, a full thickness placental-derived allograft matrix product, from Sequence LifeScience, Inc. ("Sequence"). "Rebound adds to our portfolio of placental-derived advanced biomaterial products, sales of which through the fi ...

FLORHAM PARK, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that Robert J. Hariri, M.D., Ph.D., Chairman, CEO and founder, will present at H.C. Wainwright's 26th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 9-11, 2024. H.C. Wainwright 26th Annual Globa ...

FLORHAM PARK, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the "Company"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today the appointment of Richard J. Berman, to its Board of Directors. Mr. Berman is an experienced public company director whose career spans over 40 years of venture capital, senior management, and merger and acquisitions experience. He has served as a director a ...

Celularity's expected combined net sales for the first half 2024 are $25.8 to $27.8 million compared to $6.9 million of net sales in the first of 2023 at the midpoint of the 2024 range. As reported on its Form 10-K for the year ended December 31, 2023, Celularity reported combined net sales of its advanced biomaterial product and biobanking businesses of $22.8 million for the full year 2023, consisting of advanced biomaterial product net sales of $17.3 million and biobanking net sales of $5.4 million. Repor ...